{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:24:14Z","timestamp":1792027454385,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10384-025-01237-9","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T02:36:03Z","timestamp":1750991763000},"page":"918-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Short\u2011term outcomes of switching to faricimab for macular edema secondary to retinal vein occlusion"],"prefix":"10.1007","volume":"69","author":[{"given":"Taiichi","family":"Hikichi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Kurabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amane","family":"Notoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuna","family":"Oguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeka","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"1237_CR1","first-page":"133","volume":"98","author":"R Klein","year":"2000","unstructured":"Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the beaver dam eye study. Trans Am Ophthalmol Soc. 2000;98:133\u201341.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1237_CR2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313-9.e1.","journal-title":"Ophthalmology"},{"key":"1237_CR3","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.3390\/jcm9113457","volume":"9","author":"H Noma","year":"2020","unstructured":"Noma H, Yasuda K, Shimura M. Cytokines and pathogenesis of central retinal vein occlusion. J Clin Med. 2020;9:3457.","journal-title":"J Clin Med"},{"key":"1237_CR4","doi-asserted-by":"publisher","first-page":"5185128","DOI":"10.1155\/2019\/5185128","volume":"2019","author":"H Noma","year":"2019","unstructured":"Noma H, Yasuda K, Shimura M. Cytokines and pathogenesis of macular edema in branch retinal vein occlusion. J Ophthalmol. 2019;2019:5185128. https:\/\/doi.org\/10.1155\/2019\/5185128.","journal-title":"J Ophthalmol"},{"key":"1237_CR5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","volume":"16","author":"PA Campochiaro","year":"2008","unstructured":"Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16:791\u20139.","journal-title":"Mol Ther"},{"key":"1237_CR6","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","volume":"120","author":"SR Boyd","year":"2002","unstructured":"Boyd SR, Zachary I, Chakravarthy U, Wisdom GB, Cree IA, Martin JF, et al. Correlations of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120:1644\u201350.","journal-title":"Arch Ophthalmol"},{"key":"1237_CR7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/2013.jamaophthalmol.228","volume":"131","author":"H Noma","year":"2013","unstructured":"Noma H, Mimura T, Eguchi S. Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol. 2013;131:160\u20135.","journal-title":"JAMA Ophthalmol"},{"key":"1237_CR8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Clark WL, Boyer DS, Brown DM, Haller JA, Vitti R, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016;123:330\u20136.","journal-title":"Ophthalmology"},{"key":"1237_CR9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary endpoint results of a phase III study. Ophthalmology. 2010;117:1124-33.e1.","journal-title":"Ophthalmology"},{"key":"1237_CR10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ophtha.2012.09.032","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology. 2013;120:795\u2013802.","journal-title":"Ophthalmology"},{"key":"1237_CR11","first-page":"7195","volume":"98","author":"T Hikichi","year":"2014","unstructured":"Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, et al. Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2014;98:7195\u20139.","journal-title":"Br J Ophthalmol"},{"key":"1237_CR12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema (YOSEMITE and RHINE): two randomized, double-masked, phase 3 trials. Lancet. 2022;399:741\u201355.","journal-title":"Lancet"},{"key":"1237_CR13","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3390\/cells9081869","volume":"9","author":"M Khan","year":"2020","unstructured":"Khan M, Aziz A, Shafi NA, Abas T, Khanani AM. Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab. Cells. 2020;9:1869.","journal-title":"Cells"},{"key":"1237_CR14","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin\/Tie 2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35:1305\u201316.","journal-title":"Eye"},{"key":"1237_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4419-1399-9_2","volume":"664","author":"RS Apte","year":"2010","unstructured":"Apte RS. Regulation of angiogenesis by macrophages. Adv Exp Med Biol. 2010;664:15\u20139.","journal-title":"Adv Exp Med Biol"},{"key":"1237_CR16","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s13300-022-01326-9","volume":"13","author":"JD Collazos-Aleman","year":"2022","unstructured":"Collazos-Aleman JD, Gnecco-Gonzalez S, Jaramillo-Zarama B, Jimenez-Mora MA, Mendivil CO. The role of angiopoietins in neovascular diabeties-related retinal diseases. Diabetes Ther. 2022;13:1811\u201321.","journal-title":"Diabetes Ther"},{"key":"1237_CR17","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"S Sahni","year":"2019","unstructured":"Sahni S, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126:1155\u201370.","journal-title":"Ophthalmology"},{"key":"1237_CR18","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kilre CA, Stone NM, Akil H, Gkika T, Fischer D, et al. Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema. Eye. 2024;38:3569\u201377.","journal-title":"Eye"},{"key":"1237_CR19","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, et al. Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials. Ophthalmology. 2024;131:950\u201360.","journal-title":"Ophthalmology"},{"key":"1237_CR20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/eye.2011.92","volume":"25","author":"M Laouri","year":"2011","unstructured":"Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond). 2011;25:981\u20138.","journal-title":"Eye (Lond)"},{"key":"1237_CR21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/bmj.310.6973.170","volume":"310","author":"JM Bland","year":"1995","unstructured":"Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310:170.","journal-title":"BMJ"},{"key":"1237_CR22","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2147\/OPTH.S7631","volume":"4","author":"N Karia","year":"2010","unstructured":"Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol. 2010;4:809\u201316.","journal-title":"Clin Ophthalmol"},{"key":"1237_CR23","first-page":"438412","volume":"2013","author":"A Deobhakta","year":"2013","unstructured":"Deobhakta A, Chang LK. Inflammation in retinal vein occlusion. Int J Inflamm. 2013;2013:438412.","journal-title":"Int J Inflamm"},{"key":"1237_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","volume":"277","author":"PC Maisonpierre","year":"1997","unstructured":"Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Viegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonisit for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55\u201360.","journal-title":"Science"},{"key":"1237_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nm1351","volume":"12","author":"U Fiedler","year":"2006","unstructured":"Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235\u20139.","journal-title":"Nat Med"},{"key":"1237_CR26","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.3390\/jcm12216710","volume":"12","author":"R Kurobe","year":"2023","unstructured":"Kurobe R, Hirano Y, Yuguchi T, Suzuki N, Yasukawa T. Severe macular ischemia is associated with a poor visual prognosis and serious complications in eyes with central retinal vein occlusion. J Clin Med. 2023;12:6710.","journal-title":"J Clin Med"},{"key":"1237_CR27","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.ophtha.2015.04.006","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, et al. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion. Ophthalmology. 2015;122:1426\u201337.","journal-title":"Ophthalmology"},{"key":"1237_CR28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaophthalmol.2013.5515","volume":"132","author":"SS Hayreh","year":"2014","unstructured":"Hayreh SS, Zimmerman MB. Branch retinal vein occlusion. natural history of visual outcome. JAMA Ophthalmol. 2014;132:13\u201322.","journal-title":"JAMA Ophthalmol"},{"key":"1237_CR29","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","volume":"117","author":"RL McIntosh","year":"2010","unstructured":"McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al. Natural history of central retinal vein occlusion: an evidence-based systemic review. Ophthalmology. 2010;117:1113-23.e15.","journal-title":"Ophthalmology"},{"key":"1237_CR30","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","volume":"121","author":"JS Heier","year":"2014","unstructured":"Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121:1414-20.e1.","journal-title":"Ophthalmology"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01237-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01237-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01237-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:23:23Z","timestamp":1762881803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01237-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01237-9","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T. Hikichi, None; H. Kurabe, None; A. Notoya, None; Y. Oguro, None; M. Hirano, None; Y. Doi, None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}